Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2011

View Archived Issues

Esmirtazapine may impair day-after driving performance

Yokukansan ameliorates aspects of two autism spectrum disorders

SHIFT substudy evaluates ivabradine in patients on background therapy for heart failure

Doxazosin versus tizanidine assessed in children with voiding dysfunction

Merck & Co. reports discovery of new tachykinin NK1 receptor antagonists

EVOLVE-1 trial assesses mTOR inhibitor plus best supportive care in hepatocellular carcinoma

Merck KGaA presents novel TGFR-1 inhibitors

KBP Biosciences patents novel antibacterial prodrugs of carbapenem derivatives

New prostaglandin E synthase inhibitors synthesized

Elevation Pharmaceuticals begins phase II trial of nebulized EP-101 in COPD

New substituted trifluoromethanes disclosed

Completed phase IIa study provides promising data on VX-509 in rheumatoid arthritis

Durect advances U.S. phase III Posidur trial

Adolor completes reacquisition of all rights to alvimopan

BioDelivery Sciences reports preliminary phase I data on BEMA-buprenorphine/naloxone

RIKEN identifies novel IFN-gamma inducers

Discovery Labs submits complete response to FDA for Surfaxin

Theratechnologies initiates new phase II tesamorelin study

Boehringer Ingelheim provides updates on two phase II afatinib trials in breast cancer

Basilea Pharmaceutica begins second phase I trial of sulfactam antibiotic BAL-30072

Furiex reports promising phase II data on MuDelta in D-IBS

SARcode BioScience initiates phase III trial of SAR-1118 ophthalmic solution

European Commission grants PUMA for Buccolam

AB Science commences enrollment in international masitinib trial in MS

MediGene and Pharmanova enter agreement for Veregen

University of Pennsylvania awards grant to OPKO for MPS I therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026